234 related articles for article (PubMed ID: 18081371)
1. Nonresponse to treatment for hepatitis C: current management strategies.
Yuan HJ; Lee WM
Drugs; 2008; 68(1):27-42. PubMed ID: 18081371
[TBL] [Abstract][Full Text] [Related]
2. Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C.
Hauser G; Awad T; Brok J; Thorlund K; Štimac D; Mabrouk M; Gluud C; Gluud LL
Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD005441. PubMed ID: 24585509
[TBL] [Abstract][Full Text] [Related]
3. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial.
Jensen DM; Marcellin P; Freilich B; Andreone P; Di Bisceglie A; Brandão-Mello CE; Reddy KR; Craxi A; Martin AO; Teuber G; Messinger D; Thommes JA; Tietz A
Ann Intern Med; 2009 Apr; 150(8):528-40. PubMed ID: 19380853
[TBL] [Abstract][Full Text] [Related]
4. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
Pessôa MG; Cheinquer H; Almeida PR; Silva GF; Lima MP; Paraná R; Lacerda MA; Parise ER; Pernambuco JR; Pedrosa SS; Teixeira R; Sette H; Tatsch F
Ann Hepatol; 2012; 11(1):52-61. PubMed ID: 22166561
[TBL] [Abstract][Full Text] [Related]
5. Chronic hepatitis C: management of treatment failures.
Keeffe EB
Clin Gastroenterol Hepatol; 2005 Oct; 3(10 Suppl 2):S102-5. PubMed ID: 16234055
[TBL] [Abstract][Full Text] [Related]
6. Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.
Scott LJ; Perry CM
Drugs; 2002; 62(3):507-56. PubMed ID: 11827565
[TBL] [Abstract][Full Text] [Related]
7. Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-week interim results of a pilot study.
Poo JL; Sánchez-Avila F; Kershenobich D; García-Samper X; Gongora J; Uribe M
J Gastroenterol Hepatol; 2004 Dec; 19 Suppl 6():S79-81. PubMed ID: 15546256
[TBL] [Abstract][Full Text] [Related]
8. Management of patients with chronic hepatitis C virus infection and previous nonresponse.
Shiffman ML
Rev Gastroenterol Disord; 2004; 4 Suppl 1():S22-30. PubMed ID: 15184821
[TBL] [Abstract][Full Text] [Related]
9. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
10. Eight-week regimen of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C with hepatitis C virus genotype 2 and a rapid virological response.
Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Kanamori A; Atsumi H; Nakano S; Arakawa T
Liver Int; 2009 Jan; 29(1):120-5. PubMed ID: 18384519
[TBL] [Abstract][Full Text] [Related]
11. [New trend in treatment in patients with chronic hepatitis C].
Werling K; Tulassay Z
Orv Hetil; 2006 Apr; 147(14):637-41. PubMed ID: 16711370
[TBL] [Abstract][Full Text] [Related]
12. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
[TBL] [Abstract][Full Text] [Related]
13. Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients.
Helal GK; Gad MA; Abd-Ellah MF; Eid MS
J Med Virol; 2016 Dec; 88(12):2170-2178. PubMed ID: 27183377
[TBL] [Abstract][Full Text] [Related]
14. Peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy.
Parise E; Cheinquer H; Crespo D; Meirelles A; Martinelli A; Sette H; Gallizi J; Silva R; Lacet C; Correa E; Cotrim H; Fonseca J; Paraná R; Spinelli V; Amorim W; Tatsch F; Pessoa M;
Braz J Infect Dis; 2006 Feb; 10(1):11-6. PubMed ID: 16767309
[TBL] [Abstract][Full Text] [Related]
15. Management of chronic hepatitis C patients who have relapsed or not responded to pegylated interferon alfa plus ribavirin.
Dieterich DT; Rizzetto M; Manns MP
J Viral Hepat; 2009 Dec; 16(12):833-43. PubMed ID: 19889142
[TBL] [Abstract][Full Text] [Related]
16. Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.
Katz LH; Goldvaser H; Gafter-Gvili A; Tur-Kaspa R
Cochrane Database Syst Rev; 2012 Sep; (9):CD008516. PubMed ID: 22972122
[TBL] [Abstract][Full Text] [Related]
17. Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection.
Sagir A; Heintges T; Akyazi Z; Oette M; Erhardt A; Häussinger D
Liver Int; 2007 Sep; 27(7):954-9. PubMed ID: 17696934
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of peginterferon α-2a (40 kD) plus ribavirin among patients with chronic hepatitis C and earlier treatment failure to interferon and ribavirin: an open-label study in central and Eastern Europe.
Husa P; Oltman M; Ivanovski L; Rehák V; Messinger D; Tietz A; Urbanek P
Eur J Gastroenterol Hepatol; 2011 May; 23(5):375-81. PubMed ID: 21502923
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy.
Singal AG; Waljee AK; Shiffman M; Bacon BR; Schoenfeld PS
Aliment Pharmacol Ther; 2010 Oct; 32(8):969-83. PubMed ID: 20937042
[TBL] [Abstract][Full Text] [Related]
20. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
Chung RT; Andersen J; Volberding P; Robbins GK; Liu T; Sherman KE; Peters MG; Koziel MJ; Bhan AK; Alston B; Colquhoun D; Nevin T; Harb G; van der Horst C;
N Engl J Med; 2004 Jul; 351(5):451-9. PubMed ID: 15282352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
